Brandon Capital Announces Sixth Fund with A$270 million (US$180 million) Initial Close to Drive Life Science Innovation
Posted: 27 June 2024 Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the launch of its sixth fund, Brandon Capital Fund VI, with an initial close at A$270 million (US$180 million). This new fund will…
New test promises earlier detection of dementia onset
Posted: 27 June 2024 A new test promises to predict whether someone will get dementia, almost a decade before diagnosis. An international research team, including Associate Professor Adeel Razi, from Melbourne’s Monash University, have developed a new method…
A promising vaccine approach to induce longer-lasting protective immunity against COVID-19
Posted: 27 June 2024 A scientific team from the Yong Loo Lin School of Medicine at the National University of Singapore (NUS Medicine) and Monash University has engineered a COVID-19 vaccine that induced – in pre-clinical models –…
One-two punch treatment delivers blood cancer knockout
Posted: 27 June 2024 A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukaemia (AML), one of the most common types of blood cancers. A new study by WEHI…
Clinical trials are a critical step in the research and development process for new drugs, vaccines, medical devices and diagnostics.
Posted: 27 June 2024 Participants in clinical trials get early access to these potentially life-saving new therapies, while at the same time advancing medical knowledge. More broadly, clinical trial activity contributes to the development of a thriving research…
GeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Posted: 27 July 2024 Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk…
Immutep Reports Positive Topline Results from TACTI-003 Phase IIb Trial in First Line Head and Neck Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces topline results from the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial…
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
Posted: 27 June 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company…
New WEHI spinout company tackles hard-to-treat cancers
Posted: 20 June 2024 A new WEHI spinout company launched this week will use a world-leading technology to target cancers that are difficult to treat with existing medicines. In 2023, the Albanese Government awarded $15 million in funding…
Forbes Australia recognises Professor Mimi Tang as an entrepreneur to watch
Posted: 20 June 2024 Professor Mimi Tang, Scientific Founder and CEO, Prota Therapeutics has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen…
King’s Birthday Honours for contributions in research, education and public health
Posted: 14 June 2024 Victoria’s remarkable talent shines bright in this year’s King’s Birthday Honours, including nine leaders from BioMelbourne Network member organisations – AusBiotech,…
A$7M Placement Plus SPP to Advance Development and Commercialisation of Proprietary Research Tools, Diagnostics and Therapeutics
Posted: 13 June 2024 Highlights: INOVIQ successfully completed a A$7 million placement to institutional and sophisticated investors at A$0.50 per share. INOVIQ Board and Management have participated in the placement. Funds raised will be used to advance commercialisation…
